Clinical trial
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
NCT02037529 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
- Lead sponsor
- Academic and Community Cancer Research United
- Phase
- Phase 3
- Overall status
- Suspended
- Start date
- January 17, 2014
- Completion date
- October 31, 2024
- Enrollment
- 201 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.
breast adenocarcinoma, her2/neu negative, invasive breast carcinoma, stage iiic breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7